BACKGROUND: In recent years, evidence is accumulating that cancer cells develop strategies to escape immune recognition. HLA class I HC down-regulation is one of the most investigated. In addition, different HLA haplotypes are known to correlate to both risk of acquiring diseases and also prognosis in survival of disease or cancer. We have previously shown that patients with serous adenocarcinoma of the ovary in advanced surgical stage disease have a particularly poor prognosis if they carry the HLA-A02* genotype. We aimed to study the relationship between HLA-A02* genotype in these patients and the subsequent HLA class I HC protein product defects in the tumour tissue. MATERIALS AND METHODS: One hundred and sixty-two paraffin-embedded tumour lesions obtained from Swedish women with epithelial ovarian cancer were stained with HLA class I heavy chain (HC) and β(2)-microglobulin (β(2)-m)-specific monoclonal antibodies (mAb). Healthy ovary and tonsil tissue served as a control. The HLA genotype of these patients was determined by PCR/sequence-specific primer method. The probability of survival was calculated using the Kaplan-Meier method, and the hazard ratio (HR) was estimated using proportional hazard regression. RESULTS: Immunohistochemical staining of ovarian cancer lesions with mAb showed a significantly higher frequency of HLA class I HC and β(2)-m down-regulation in patients with worse prognosis (WP) than in those with better prognosis. In univariate analysis, both HLA class I HC down-regulation in ovarian cancer lesions and WP were associated with poor survival. In multivariate Cox-analysis, the WP group (all with an HLA-A02* genotype) had a significant higher HR to HLA class I HC down-regulation. CONCLUSIONS: HLA-A02* is a valuable prognostic biomarker in epithelial ovarian cancer. HLA class I HC loss and/or down-regulation was significantly more frequent in tumour tissues from HLA-A02* positive patients with serous adenocarcinoma surgical stage III-IV. In multivariate analysis, we show that the prognostic impact is reasonably correlated to the HLA genetic rather than to the expression of its protein products.
BACKGROUND: In recent years, evidence is accumulating that cancer cells develop strategies to escape immune recognition. HLA class I HC down-regulation is one of the most investigated. In addition, different HLA haplotypes are known to correlate to both risk of acquiring diseases and also prognosis in survival of disease or cancer. We have previously shown that patients with serous adenocarcinoma of the ovary in advanced surgical stage disease have a particularly poor prognosis if they carry the HLA-A02* genotype. We aimed to study the relationship between HLA-A02* genotype in these patients and the subsequent HLA class I HC protein product defects in the tumour tissue. MATERIALS AND METHODS: One hundred and sixty-two paraffin-embedded tumour lesions obtained from Swedish women with epithelial ovarian cancer were stained with HLA class I heavy chain (HC) and β(2)-microglobulin (β(2)-m)-specific monoclonal antibodies (mAb). Healthy ovary and tonsil tissue served as a control. The HLA genotype of these patients was determined by PCR/sequence-specific primer method. The probability of survival was calculated using the Kaplan-Meier method, and the hazard ratio (HR) was estimated using proportional hazard regression. RESULTS: Immunohistochemical staining of ovarian cancer lesions with mAb showed a significantly higher frequency of HLA class I HC and β(2)-m down-regulation in patients with worse prognosis (WP) than in those with better prognosis. In univariate analysis, both HLA class I HC down-regulation in ovarian cancer lesions and WP were associated with poor survival. In multivariate Cox-analysis, the WP group (all with an HLA-A02* genotype) had a significant higher HR to HLA class I HC down-regulation. CONCLUSIONS: HLA-A02* is a valuable prognostic biomarker in epithelial ovarian cancer. HLA class I HC loss and/or down-regulation was significantly more frequent in tumour tissues from HLA-A02* positive patients with serous adenocarcinoma surgical stage III-IV. In multivariate analysis, we show that the prognostic impact is reasonably correlated to the HLA genetic rather than to the expression of its protein products.
Authors: Jeffrey P North; John T Vetto; Rajmohan Murali; Kevin P White; Clifton R White; Boris C Bastian Journal: Am J Surg Pathol Date: 2011-08 Impact factor: 6.394
Authors: Jeffrey A Sosman; Joseph M Unger; P-Y Liu; Lawrence E Flaherty; Min S Park; Raymond A Kempf; John A Thompson; Paul I Terasaki; Vernon K Sondak Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Jeffrey E Lee; Joseph Abdalla; Geoffrey A Porter; Loretta Bradford; Elizabeth A Grimm; John D Reveille; Paul F Mansfield; Jeffrey E Gershenwald; Merrick I Ross Journal: Ann Surg Oncol Date: 2002-07 Impact factor: 5.344
Authors: Luigi De Petris; Kjell Bergfeldt; Christina Hising; Andreas Lundqvist; Bengt Tholander; Pavel Pisa; Henk G M van der Zanden; Giuseppe Masucci Journal: Med Oncol Date: 2004 Impact factor: 3.064
Authors: Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand Journal: Mol Cancer Ther Date: 2015-12-30 Impact factor: 6.261
Authors: Elien M Doorduijn; Marjolein Sluijter; Bianca J Querido; Cláudia C Oliveira; Adnane Achour; Ferry Ossendorp; Sjoerd H van der Burg; Thorbald van Hall Journal: J Clin Invest Date: 2016-01-19 Impact factor: 14.808
Authors: Loren Gragert; Stephanie Fingerson; Mark Albrecht; Martin Maiers; Matt Kalaycio; Brian T Hill Journal: Blood Date: 2014-09-17 Impact factor: 22.113
Authors: Anders Näsman; Emilia Andersson; Linda Marklund; Nikolaos Tertipis; Lalle Hammarstedt-Nordenvall; Per Attner; Tommy Nyberg; Giuseppe V Masucci; Eva Munck-Wikland; Torbjörn Ramqvist; Tina Dalianis Journal: PLoS One Date: 2013-10-10 Impact factor: 3.240
Authors: Emilia Andersson; Isabel Poschke; Lisa Villabona; Joseph W Carlson; Andreas Lundqvist; Rolf Kiessling; Barbara Seliger; Giuseppe V Masucci Journal: Oncoimmunology Date: 2015-07-25 Impact factor: 8.110
Authors: Hao Hong; Christine E Brown; Julie R Ostberg; Saul J Priceman; Wen-Chung Chang; Lihong Weng; Paul Lin; Mark T Wakabayashi; Michael C Jensen; Stephen J Forman Journal: PLoS One Date: 2016-01-13 Impact factor: 3.240